Dare Bioscience, Inc. 8-K

What Happened Dare Bioscience, Inc. announced in an 8-K filed May 18, 2026 that it completed the closings of its Regulation A offering on May 14, 2026. The company issued 50,000 Investor Units at $5.00 per unit (totaling $250,000). Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two warrants (Investor Warrants), which together allow purchase of up to 100,000 shares of common stock. The offering was conducted under the company’s Form 1‑A (File No. 024-12688), qualified by the SEC on April 1, 2026.

Key Details

• 50,000 Investor Units issued at $5.00 per unit — gross proceeds of $250,000.
• Each unit = 1 share of Series A Convertible Preferred Stock + 2 Investor Warrants; warrants cover up to 100,000 common shares.
• Offering conducted pursuant to Form 1‑A (qualified April 1, 2026) and offering circulars (most recent supplements dated March 26 and May 14, 2026).
• Terms of conversion/exercise were previously disclosed in the company’s Jan. 29, 2026 Form 8‑K.

Why It Matters This transaction provided Dare immediate capital of $250,000 under its Regulation A program and added securities that could convert or be exercised into common shares. Investors should note the potential dilution from the warrants (up to 100,000 shares) and the Series A preferred conversion — details are in the previously filed offering documents and the Jan. 29, 2026 8‑K. The filing is a straightforward disclosure of the completed unregistered sale under the company’s qualified offering.